| Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis |
Psoriasis |
Drug: Guselkumab|Drug: Placebo |
Janssen Research & Development, LLC |
Phase 3 |
| A Study of LY3074828 in Participants With Moderate to Severe Plaque Psoriasis |
Plaque Psoriasis |
Drug: LY3074828|Drug: Placebo |
Eli Lilly and Company |
Phase 2 |
| Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp |
Actinic Keratosis |
Drug: ALA|Drug: Vehicle|Device: IBL 20 mW|Device: IBL 10 mW |
DUSA Pharmaceuticals, Inc. |
Phase 3 |
| A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis |
Plaque Psoriasis |
Drug: 122-0551 Foam|Drug: Vehicle Foam |
Therapeutics, Inc. |
Phase 3 |
| Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis |
Actively Extending Plaque Psoriasis|Moderate to Severe Plaque Psoriasis |
Drug: IMO-3100|Drug: Saline for Injection|Drug: IMO-3100 |
Idera Pharmaceuticals, Inc. |
Phase 2 |
| A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris |
Acne Vulgaris |
Drug: adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Drug: EPIDUO|Drug: Placebo (Vehicle Gel) |
Actavis Mid-Atlantic LLC |
|
| Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo |
Rosacea |
Drug: Doxycycline|Other: Placebo |
Galderma Laboratories, L.P. |
Phase 4 |
| A Dose-Finding Study of GSK2894512 Cream in Subjects With Plaque Psoriasis |
Psoriasis |
Drug: GSK2894512 1% Cream|Drug: GSK2894512 0.5% Cream|Drug: Vehicle cream |
GlaxoSmithKline |
Phase 2 |
| Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis |
Plaque Psoriasis |
Drug: IDP-122 Lotion|Drug: IDP-122 Vehicle Lotion |
Valeant Pharmaceuticals International, Inc. |
Phase 3 |
| A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis |
Psoriasis |
Drug: JNJ-38518168 60 mg|Drug: JNJ-38518168 30 mg|Drug: JNJ-38518168 3 mg|Drug: Placebo |
Janssen Research & Development, LLC |
Phase 2 |
| A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305) |
Plaque Psoriasis |
Drug: 000-0551 Lotion|Drug: Vehicle Lotion |
Therapeutics, Inc. |
Phase 3 |
| BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris |
Acne Vulgaris |
Drug: BLI1100|Drug: BLI1100 – modified formulation|Drug: Placebo |
Braintree Laboratories |
Phase 2 |
| Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis |
Psoriasis |
Drug: IDP-118 Lotion|Drug: Tazorac Cream|Drug: IDP-118 Vehicle Lotion|Drug: IDP-118 Vehicle Cream |
Valeant Pharmaceuticals International, Inc. |
Phase 2 |
| Microneedle Lesion Preparation Prior to ALA-PDT for AK on Face |
Actinic Keratosis |
Drug: ALA|Drug: Topical Solution Vehicle|Device: IBL 10 mW|Procedure: Microneedle lesion preparation|Device: IBL 20 mW |
DUSA Pharmaceuticals, Inc. |
Phase 2 |
| An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients |
Psoriasis |
Drug: VTP-43742|Drug: Placebo 1|Drug: Placebo 2 |
Vitae Pharmaceuticals, Inc. |
Phase 1|Phase 2 |
| A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) |
Androgenetic Alopecia |
Drug: SM04554|Drug: Vehicle |
Samumed LLC |
Phase 2 |
| To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel |
Acne Vulgaris |
Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug: DUAC® Gel|Drug: Placebo |
Cadila Healthcare Limited |
Phase 3 |
| Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK) |
Actinic Keratosis |
Drug: Broad Area ALA 1-hour incubation|Drug: Broad Area ALA 2 hour incubation|Drug: broad area ALA 3-hour incubation|Drug: Spot ALA 2 hour incubation|Drug: Vehicle PDT|Device: Blue Light Treatment |
DUSA Pharmaceuticals, Inc. |
Phase 2 |
| Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis |
Psoriasis |
Drug: IDP-118 Lotion|Drug: HP Monad Lotion|Drug: Ultravate Cream|Drug: Tazorac Cream |
Valeant Pharmaceuticals International, Inc. |
Phase 1 |
| Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses |
Actinic Keratosis |
Drug: GDC 695|Drug: Diclofenac Sodium Gel, 3%|Drug: Vehicle gel |
Gage Development Company, LLC |
Phase 3 |
| Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris |
Acne |
Drug: IDP-121 Lotion|Drug: IDP-121 Vehicle Lotion |
Valeant Pharmaceuticals International, Inc. |
Phase 1 |
| A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris |
Acne Vulgaris |
Drug: Tazarotene Cream 0.1%|Drug: Tazorac®|Drug: Placebo |
Fougera Pharmaceuticals Inc. |
Phase 3 |
| A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis |
Plaque Psoriasis |
Drug: Tazarotene Cream 0.05%|Drug: TAZORAC® (tazarotene) Cream 0.05%|Drug: Placebo |
Fougera Pharmaceuticals Inc. |
Phase 3 |
| Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis |
Atopic Dermatitis |
Drug: PF-04965842|Drug: PF-04965842|Drug: PF-04965842|Drug: PF-04965842|Drug: Placebo |
Pfizer |
Phase 2 |
| BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis |
Psoriasis |
Drug: ABBV-066|Drug: ustekinumab|Drug: placebo to ABBV-066|Drug: placebo to ustekinumab |
AbbVie|Boehringer Ingelheim |
Phase 3 |
| An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris |
Acne Vulgaris |
Drug: CB-03-01 cream, 1% |
Cassiopea SpA |
Phase 3 |
| BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment |
Psoriasis |
Drug: ABBV-066|Drug: Placebo |
AbbVie|Boehringer Ingelheim |
Phase 3 |
| A Study of Equivalence of Generic Ingenol Mebutate Gel 0.05% and Picato Gel 0.05% in Subjects With Actinic Keratosis |
Actinic Keratosis |
Drug: Ingenol Mebutate (Picato®)|Drug: Generic Ingenol Mebutate|Drug: Vehicle Foam |
Actavis Inc. |
Phase 3 |
| Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis |
Actinic Keratosis |
Drug: Carac Cream|Drug: Generic Fluorouracil Cream|Drug: Placebo |
Actavis Inc. |
Phase 3 |
| A Study to Evaluate the Safety and Efficacy of CB-03-01 Cream, 1% in Subjects With Facial Acne Vulgaris (25) |
Acne Vulgaris |
Drug: CB-03-01 cream, 1%|Drug: Vehicle cream |
Cassiopea SpA |
Phase 3 |
| A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris |
Acne Vulgaris |
Drug: BLI1100-1|Drug: BLI1100-2|Drug: BLI1100-3|Drug: Control group|Drug: Placebo |
Braintree Laboratories |
Phase 2 |
| Study to Evaluate the Safety and Efficacy of a Once-Daily CLS001 Topical Gel Versus Vehicle |
Rosacea |
Drug: Omiganan|Drug: Vehicle |
Cutanea Life Sciences, Inc. |
Phase 3 |
| Study to Evaluate the Long-term Safety of a Once-Daily Omiganan Topical Gel |
Rosacea |
Drug: Omiganan |
Cutanea Life Sciences, Inc. |
Phase 3 |
| Efficacy and Safety of CD5789 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris |
Acne Vulgaris |
Drug: CD5789 50μg/g cream|Drug: Placebo cream |
Galderma R&D |
Phase 3 |
| Long-term Safety Study of DRM04 in Subjects With Primary Axillary Hyperhidrosis |
Hyperhidrosis |
Drug: DRM04 Topical Wipes |
Dermira, Inc. |
Phase 3 |
| Study of DRM04 in Axillary Hyperhydrosis |
Hyperhidrosis |
Drug: DRM04 Topical Wipes|Other: Placebo |
Dermira, Inc. |
Phase 3 |
| Finasteride Treatment of Severe Nodulocystic Acne |
NODULOCYSTIC ACNE |
Drug: Finasteride 23.5 mg tablets|Drug: Finasteride 33.5 mg tablets|Drug: Placebo tablets |
Elorac, Inc. |
Phase 2 |
| A Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis |
Hyperhidrosis |
Drug: BBI-4000 Low Concentration|Drug: BBI-4000 Middle Concentration|Drug: BBI-4000 High Concentration|Drug: Placebo |
Brickell Biotech, Inc. |
Phase 2 |
| Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne |
Acne Vulgaris |
Drug: Sarecycline|Drug: Placebo |
Warner Chilcott |
Phase 3 |
| Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis |
Dermatitis, Atopic |
Drug: dupilumab|Drug: placebo |
Regeneron Pharmaceuticals|Sanofi |
Phase 3 |
| Study of Dupilumab (REGN668/ SAR231893) and Immune Responses in Adults With Atopic Dermatitis (AD) |
Atopic Dermatitis |
Drug: Dupilumab|Drug: placebo |
Regeneron Pharmaceuticals|Sanofi |
Phase 2 |
| Twelve Month Follow-Up of CP0108 |
Actinic Keratosis |
Drug: Aminolevulinic Acid (ALA)|Drug: Topical Solution Vehicle|Device: BLU-U Blue Light Photodynamic Therapy Illuminator |
DUSA Pharmaceuticals, Inc. |
Phase 3 |
| A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment |
Psoriasis |
Drug: Guselkumab 100 mg|Drug: Placebo for guselkumab|Drug: Adalimumab|Drug: Placebo for adalimumab |
Janssen Research & Development, LLC |
Phase 3 |
| A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis |
Psoriasis |
Drug: Guselkumab 100 mg|Drug: Placebo for guselkumab|Drug: Adalimumab|Drug: Placebo for adalimumab |
Janssen Research & Development, LLC |
Phase 3 |
| A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab |
Psoriasis |
Drug: Ustekinumab|Drug: Guselkumab|Drug: Placebo for ustekinumab|Drug: Placebo for guselkumab |
Janssen Research & Development, LLC |
Phase 3 |
| Safety and Efficacy Study of Photodynamic Therapy With Levulan Kerastick + Blue Light for Actinic Keratoses on the Upper Extremities |
Actinic Keratosis |
Drug: Aminolevulinic Acid (ALA)|Drug: Topical Solution Vehicle|Device: Blue Light Photodynamic Therapy Illuminator (BLU-U) |
DUSA Pharmaceuticals, Inc. |
Phase 3 |
| Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) |
Plaque Psoriasis |
Drug: Etanercept|Drug: CHS-0214 |
Coherus Biosciences, Inc.|Baxalta US Inc. |
Phase 3 |
| A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea |
Rosacea |
Drug: Azelaic acid |
Actavis Inc. |
Phase 3 |
| A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses |
Actinic Keratosis |
Drug: Imiquimod |
Actavis Inc. |
Phase 3 |
| Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis |
Actinic Keratosis |
Drug: LEO 43204|Drug: Placebo |
LEO Pharma |
Phase 1|Phase 2 |
| Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Adalimumab (GP2017) and Humira |
Plaque Type Psoriasis |
Drug: GP2017 Adalimumab|Drug: Humira ® Adalimumab |
Sandoz |
Phase 3 |
| A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis |
Actinic Keratosis |
Drug: Diclofenac sodium|Other: Placebo |
Actavis Inc. |
Phase 3 |
| VPD-737 for Treatment of Chronic Pruritus |
Chronic Pruritus |
Drug: VPD-737|Drug: Placebo |
Menlo Therapeutics Inc. |
Phase 2 |
| Open-label Study of Dupilumab (REGN668/SAR231893) in Patients With Atopic Dermatitis |
Atopic Dermatitis |
Drug: Dupilumab (REGN668/SAR231893) |
Regeneron Pharmaceuticals|Sanofi |
Phase 3 |
| A Comparison of DFD01 Spray Versus Comp01 Lotion, Vehicle Spray and Vehicle Lotion in Subjects With Moderate Psoriasis |
Psoriasis |
Drug: DFD01 Spray|Drug: Comp01 Lotion|Drug: Vehicle Lotion|Drug: Vehicle Spray |
Promius Pharma, LLC |
Phase 3 |
| Study to Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis |
Psoriasis |
Drug: M518101|Drug: Vehicle |
Maruho North America Inc. |
Phase 3 |
| Study of Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects |
Moderate to Severe Plaque Psoriasis |
Drug: 210 mg brodalumab|Drug: 140 mg brodalumab|Drug: ustekinumab|Drug: placebo |
Amgen |
Phase 3 |
| Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis |
Actinic Keratosis |
Drug: Imiquimod Cream, 3.75%|Drug: Zyclara®|Other: Vehicle of Test Product |
Teva Pharmaceuticals USA |
Phase 3 |
| A Phase 2 Dose Escalating Study to Evaluate the Safety and Efficacy of CB-03-01 Cream in Subjects With Facial Acne Vulgaris |
Acne Vulgaris |
Drug: CB-03-01|Drug: Vehicle|Drug: CB-03-01 |
Intrepid Therapeutics, Inc. |
Phase 2 |
| An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC) |
Basal Cell Carcinoma |
|
Genentech, Inc. |
|
| A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) |
Psoriasis |
Drug: 80 mg ixekizumab Dosing Regimen|Drug: 50 mg etanercept|Drug: Placebo |
Eli Lilly and Company |
Phase 3 |
| To Evaluate the Safety, Tolerability and Efficacy of Calcipotriene Foam, 0.005%, Versus Vehicle Foam in Pediatric Subjects (Ages 2-11) With Plaque Psoriasis |
Psoriasis |
Drug: STF 115469 Foam|Drug: Vehicle Foam |
GlaxoSmithKline |
Phase 3 |
| Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea |
Papulopustular Rosacea |
Drug: Azelaic acid foam, 15% (BAY39-6251)|Drug: Vehicle foam |
Bayer |
Phase 3 |
| A Study of Ustekinumab to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis |
Psoriasis |
Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg|Drug: Placebo |
Janssen Biotech, Inc. |
Phase 3 |
| Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab |
Psoriasis |
Drug: Etanercept |
Amgen |
Phase 4 |
| A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp |
Actinic Keratosis |
Procedure: Cryotherapy|Drug: Vehicle|Drug: Ingenol metabute |
LEO Pharma |
Phase 3 |
| LEO 90100 in the Treatment of Psoriasis Vulgaris |
Psoriasis Vulgaris |
Drug: LEO 90100|Drug: Calcipotriol|Drug: Betamethasone |
LEO Pharma |
Phase 2 |
| LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris |
Psoriasis Vulgaris |
Drug: LEO 90100|Drug: Betamethasone plus calcipotriol|Drug: Ointment vehicle|Drug: LEO 90100 vehicle |
LEO Pharma |
Phase 2 |
| A Therapeutic Equivalence Study of Two Metronidazole 1%Topical Gel Treatments for Patients With Rosacea |
Rosacea |
Drug: Metronidazole Topical Gel 1%|Drug: Metronidazole Topical Gel 1% (Metrogel)|Drug: Placebo |
Taro Pharmaceuticals USA |
Phase 1 |
| A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses |
Actinic Keratoses |
Drug: imiquimod cream, 3.75%|Drug: Vehicle Cream|Drug: imiquimod cream, 3.75% |
Actavis Mid-Atlantic LLC |
|
| Phase 3 Papulopustular Rosacea Study |
Papulopustular Rosacea (PPR) |
Drug: CD5024|Drug: Azelaic acid 15% Gel |
Galderma |
Phase 3 |
| BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris |
Acne Vulgaris |
Drug: BLI1100|Drug: Vehicle cream |
Braintree Laboratories |
Phase 2 |
| A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris |
Acne Vulgaris |
Drug: Low Strength IDP-107|Drug: High Strength IDP-107|Drug: Placebo |
Dow Pharmaceutical Sciences |
Phase 2 |
| LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs) |
Psoriasis Vulgaris |
Drug: Calcipotriol plus betamethasone|Drug: Betamethasone-17,21-dipropionate|Drug: Calcipotriene|Drug: Topical suspension vehicle |
LEO Pharma |
Phase 3 |
| Efficacy and Safety of CIP-Isotretinoin in Patients With Severe Recalcitrant Nodular Acne |
Severe Nodular Acne |
Drug: CIP-Isotretinoin|Drug: Isotretinoin |
Cipher Pharmaceuticals Inc. |
Phase 3 |
| A Long Term Follow up Study of Patients Who Have Completed the PEP005-016 or PEP005-025 Studies |
Actinic Keratosis |
Drug: Lesion count |
Peplin|TKL Research, Inc. |
Phase 3 |
| A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp) |
Actinic Keratosis |
Drug: PEP005 (Ingenol Mebutate) gel, 0.015%|Drug: Vehicle Gel |
Peplin |
Phase 3 |
| Bioequivalence Study of Two Imiquimod Cream 5% |
Actinic Keratosis |
Drug: Imiquimod 5% manufactured by Taro|Drug: Aldara – Imiquimod 5%|Drug: Imiquimod Vehicle manufactured by Taro |
Taro Pharmaceuticals USA |
Phase 1 |
| Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema |
Eczema |
Drug: alitretinoin|Drug: Placebo |
Stiefel, a GSK Company|Basilea Pharmaceutica|GlaxoSmithKline |
Phase 3 |
| Chronic Plaque Psoriasis (Ps) Registry |
Chronic Plaque Psoriasis |
|
AbbVie (prior sponsor, Abbott)|AbbVie |
|
| A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations |
Actinic Keratoses |
Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel |
Peplin |
Phase 3 |
| Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
Moderate to Severe Plaque Psoriasis |
Biological: ABT-874|Biological: etanercept|Drug: placebo |
AbbVie (prior sponsor, Abbott)|Paragon Biomedical|AbbVie |
Phase 3 |
| Open Label Continuation Study in Moderate to Severe Psoriasis |
Moderate to Severe Plaque Psoriasis |
Drug: ABT-874 |
AbbVie (prior sponsor, Abbott)|AbbVie |
Phase 3 |
| Psoriasis Longitudinal Assessment and Registry (PSOLAR) |
Psoriasis|Arthritis, Psoriatic |
Biological: ustekinumab|Biological: Biological therapies other than infliximab and ustekinumab|Drug: conventional systemic agents|Biological: infliximab |
Janssen Scientific Affairs, LLC |
|
| A Pediatric Longitudinal Evaluation to Assess the Long-Term Safety of Protopic for the Treatment of Atopic Dermatitis |
Atopic Dermatitis |
|
LEO Pharma |
|
| A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE) |
Psoriasis |
|
Genentech, Inc. |
Phase 4 |